Property	Value
Status
Version
Ad File
Disable Ads Flag
Environment
Moat Init
Moat Ready
Contextual Ready
Contextual URL
Contextual Initial Segments
Contextual Used Segments
AdUnit
SubAdUnit
Custom Targeting
Ad Events
Invalid Ad Sizes

Sara M. Tolaney MD, MPH Advisory Board

See All Experts

story of the week

Published in Oncology

Journal Scan / Research · November 10, 2014

Early PET Assessment and Addition of Bevacizumab in HER2-Positive Breast Cancer

The Lancet Oncology

Save Recommend

Sign in to PracticeUpdate

Only registered members have full access to PracticeUpdate content.

Not a member?

Join for free

Disclosure statements are available on the authors' profiles:

Lee Schwartzberg MD, FACP

The Lancet Oncology

Use of [1⁸F]-FDG PET to Predict Response to Neoadjuvant Trastuzumab and Docetaxel in Patients With HER2-Positive Breast Cancer, and Addition of Bevacizumab to Neoadjuvant Trastuzumab and Docetaxel in [1⁸F]-FDG PET-Predicted Non-Responders (AVATAXHER): An Open-Label, Randomized Phase 2 Trial

Lancet Oncol 2014 Oct 30;[EPub Ahead of Print], B Coudert, J-Y Pierga, M-A Mouret-Reynier, K Kerrou, J-M Ferrero, T Petit, P Kerbrat, P-F Dupré, T Bachelot, P Gabelle, S Giard, D Coeffic, P Bougnoux, J-B Prevost, G Paintaud, G Thibault, J Hernandez, M Coudert, L Arnould, A Berriolo-Riedinger

Early PET Assessment and Addition of Bevacizumab in HER2-Positive Breast Cancer

Additional Info

Use of [1⁸F]-FDG PET to Predict Response to Neoadjuvant Trastuzumab and Docetaxel in Patients With HER2-Positive Breast Cancer, and Addition of Bevacizumab to Neoadjuvant Trastuzumab and Docetaxel in [1⁸F]-FDG PET-Predicted Non-Responders (AVATAXHER): An Open-Label, Randomized Phase 2 Trial

Further Reading

Invasive Disease–Free Survival Outcomes With SLNB vs Omission of Axillary Surgery in Patients With Early-Stage Breast Cancer Treated With Breast-Conserving Surgery

Imlunestrant With or Without Abemaciclib in Advanced Breast Cancer

Genomic Instability in Non–Breast or Ovarian Malignancies Among Individuals With Germline Pathogenic Variants in BRCA1/2

Daratumumab or Active Monitoring for High-Risk Smoldering Multiple Myeloma

Brentuximab Vedotin, Nivolumab, Doxorubicin, and Dacarbazine for Advanced-Stage Classical Hodgkin Lymphoma

Obecabtagene Autoleucel for Adults With B-Cell Acute Lymphoblastic Leukemia

De-Escalated Neoadjuvant Weekly Nab-Paclitaxel With Trastuzumab and Pertuzumab vs Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab for HER2-Positive Early Breast Cancer

Blinatumomab in Children With Standard-Risk B-Cell Acute Lymphoblastic Leukemia

Tremelimumab and Durvalumab as Neoadjuvant or Non-Operative Management Strategy for Microsatellite Instability–High Resectable Gastric or Gastroesophageal Junction Adenocarcinoma

Efficacy and Safety of Prostate Radiotherapy in Patients With De Novo Metastatic Castration-Sensitive Prostate Cancer

An Integrative Precision Medicine Approach Using Genomics and Avatar Models to Guide Treatment in Pancreatic Cancer

Recently Updated